论文部分内容阅读
细胞因子诱导的杀伤细胞(CIK)细胞是通过采集患者外周血的单核细胞,在体外经多种细胞因子诱导和培养后获得的一类具有非主要组织相容性抗原限制性(MHC)杀瘤活性的免疫细胞,同时表达CD3和CD56这两种膜蛋白分子,具有T淋巴细胞的强大抗瘤活性和NK细胞的非MHC限制性杀瘤的优点。因其易获得,体外高扩增率以及非MHC限制性等优点,使之成为肿瘤获得性生物免疫治疗中的热点。在体外及动物试验中,CIK细胞对实体瘤和血液系统恶性肿瘤同样具有有效的细胞毒性作用,临床研究显示,CIK细胞免疫治疗对于肿瘤患者,甚至是晚期肿瘤患者疗效肯定,与传统治疗方法具有协同抗瘤作用。本文将讨论CIK免疫治疗在血液系统恶性肿瘤中的研究进展及未来发展趋势,并将最新的重点研究成果作一回顾。总体来讲,研究显示,CIK细胞在控制血液系统肿瘤生长、延长生存时间以及改善生活质量上具有肯定疗效。然而,目前为止,仍缺乏明确的能够用于临床治疗的应用规范。
Cytokine-induced killer (CIK) cells are obtained by collecting peripheral blood mononuclear cells of a patient with a variety of non-major histocompatibility antigen-restricted (MHC) killer cells that have been induced and cultured in vitro by various cytokines Tumor-activating immune cells, which express both CD3 and CD56 membrane protein molecules, possess the potent antitumor activity of T lymphocytes and the non-MHC-restricted antitumor activity of NK cells. Because of its easy access, high amplification rate in vitro and non-MHC restriction, it has become a hot spot in tumor-acquired biological immunotherapy. In vitro and animal experiments, CIK cells on the solid tumor and hematological malignancies also have effective cytotoxicity, clinical studies have shown that, CIK cell immunotherapy for patients with cancer, and even patients with advanced cancer is positive, with the traditional treatment methods have Synergistic anti-tumor effect. This article will discuss CIK immunotherapy in hematological malignancies in the research progress and future trends, and the latest key findings for a review. Overall, studies have shown that CIK cells have a positive effect on controlling blood system tumor growth, prolonging survival and improving quality of life. However, so far, there is still a lack of a clear application protocol that can be used for clinical treatment.